AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04837495 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: right stellate ganglion block
Description: The skin should be anaesthetised with lidocaine 2%. Using a lateral approach and in-plane imaging, a blunt regional anaesthesia needle should be advanced deep to the carotid sheath towards the longus colli muscle. Following careful aspiration, inject 10 ml lidocaine 2% that will result in expansion of the fascia of the longus colli. Confirmation of the SGB success can be detected by warming of left upper limb and left Horner's syndrome.
Study NCT05765591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balneotherapy and aquatic exercises
Description: Information has already been included in arm/group descriptions
Study NCT04724837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan
Description: Participants will receive zibotentan as per the arms they are randomized.
Study NCT04724837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Participants will receive 10 mg dapagliflozin as per the arms they are randomized.
Study NCT04724837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo as per the arms they are randomized to.
Study NCT05163639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive pairing of cortical and spinal stimulation
Description: Transcranial magnetic stimulation (TMS) threshold, Transcutaneous spinal cord stimulation (TSCS) threshold, and peripheral and central motor conduction times will be determined. In the active intervention, two TMS pulse intensities will be tested: 90% and 120% of motor threshold. Two conditioning TSCS pulse intensities will be tested: 50% and 90% of response threshold. Single TSCS pulses will be delivered timed to arrive in the cervical spinal cord at a range of intervals from 30ms before to 30ms after the TMS pulse. The control conditions will include TMS only TSCS only and non-convergent pairing latency pairing stimulation.
Study NCT05490303 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: recording of the probe position
Description: For each patient, a cardiac ultrasound acquisition will be performed with an optical tracking system (infrared) recording the probe's position in real time.
Study NCT05163639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative pairing of cortical and spinal stimulation
Description: The surgeon will position spinal cord electrodes on the epidural surface one level rostral (typically C4/C5) to the site of myelopathy. Spinal and cortical thresholds will be determined. Investigator will then test the immediate effects of paired stimulation by stimulating the cortex at 120% of threshold and the spinal cord at 90% of threshold at various latencies relative to the time of synchronous convergence. The control intervention will include cortical only (120%) spinal only (90%) and non-convergent latency pairing stimulation.
Study NCT05163639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive repeated pairing of cortical and spinal stimulation (SCAP)
Description: Thresholds will be determined as above. Immediately prior to repetitive pairing, a set of 12 TMS pulses will be delivered at 120% threshold to measure the baseline cortical MEP. Likewise, a set of 12 TSCS pulses will be delivered at 120% of threshold to establish the baseline spinal MEP. For each session, baseline maximal pinch dynamometry will be determined. Immediately after the SCAP protocol is completed, response to TMS, TSCS, and maximal pinch dynamometry will be measured again every 10 minutes over the subsequent hour. The control conditions will include TMS only TSCS only and non-convergent pairing latency pairing stimulation.
Study NCT05163639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative repeated pairing of cortical and spinal stimulation (SCAP)
Description: Intraoperative: Spinal and cortical thresholds will be determined. Immediately prior to repetitive pairing, a set of 12 baseline cortical pulses and 12 baseline spinal pulses will be delivered at 120% threshold. SCAP protocol will be applied, both of which have been successful at inducing lasting effects in the rat. After pairing, cortical stimulation at 120% of threshold and spinal cord stimulation at 120% threshold will be repeated every 10 minutes for the duration of surgery. In a subset of patients repeated pairing will be conducted with a latency that investigator does not expect will induce SCAP, or with electrodes placed over the ventral epidural surface. The control intervention will include repeated pairing at a non-convergent latency, as well as pairing of cortical stimulation with ventral epidural stimulation.
Study NCT05163639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative repeated pairing of cortical and spinal stimulation (SCAP) at or below myelopathic region
Description: As per the intervention 'Intraoperative repeated pairing of cortical and spinal stimulation (SCAP)' targeted at or below myelopathic region.
Study NCT05090865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Liberalized dietary potassium via fruits and vegetables
Description: On the liberalized dietary potassium intervention, participants will receive groceries delivered to their houses that contain potassium rich fruit and vegetables, that contain more than 250 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 2000 mg of potassium a day from delivered fruit and vegetables, and a daily dietary potassium intake of 3500 mg.
Study NCT04956952 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EECP
Description: 1 hour of treatment with EECP
Study NCT05090865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard dietary potassium restriction
Description: Participants will receive weekly supplementation of lower potassium fruit and vegetables, that deliver less than 200 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 500 mg of K a day from the box, and a daily dietary K intake \< 2000 mg. Participants will receive counselling from a registered dietician (RD) to reinforce the potassium restriction.
Study NCT05846893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeQuent® Please NEO drug-coated balloon catheter
Description: Treatment of coronary artery disease with SeQuent® Please NEO for de novo lesions in native large coronary arteries
Study NCT05846893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Current-generation drug-eluting stent
Description: Treatment of coronary artery disease with current-generation drug-eluting stent for de novo lesions in native large coronary arteries
Study NCT05770570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: In-person individual diet and physical activity (PA) counseling
Study NCT05770570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messages
Description: Thrice-weekly diet/physical activity(PA) text messages
Study NCT05770570 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Phone calls
Description: Weekly telephone support
Study NCT05770570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone calls
Description: Weekly telephone support
Study NCT05770570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring tools
Description: Self-monitoring tools
Study NCT04683562 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pregnant women at 28-32 weeks
Description: Pregnant women at gestational age 28-32 weeks
Study NCT04683562 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: at delivery
Description: women delivered at term
Study NCT04810481 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIS Complete Monitoring System
Description: The BIS™ complete monitoring system is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS™ complete system processes raw EEG signals to produce a single number, called the BIS™ index, which correlates with the patient's level of hypnosis. A sensor placed on the patient's head transmits EEG signals to the BISx™ unit. The BIS™ unit filters and digitizes the signal, analyzes it for the artifact, and processes it using digital signal processing techniques to derive processed EEG parameters to a single Bispectral Index (BIS™), and finally sends the processed data to the monitor for display. The purpose of processing the EEG waveform data is to extract characteristic features from the complex signal that the BIS™ algorithm can utilize to derive BIS Index.
Study NCT05770570 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-monitoring tools
Description: Self-monitoring tools
Study NCT04774445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyCancerGene
Description: Interactive Health Communication Application
Study NCT05835323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted mini-PCNL
Description: Eligible participants will be enrolled to undergo robotic-assisted PCNL using the MONARCH Platform, Urology for the removal of kidney stones. The MONARCH Platform, Urology is a novel flexible robotic device that enables the clinician to obtain both transurethral and percutaneous access to a participant's kidney under continuous visualization for therapeutic application (for example, stone removal).
Study NCT04665765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04665765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT04665765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT04665765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Given IV
Study NCT04665765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04818229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-307
Description: CBP-307 capsules oral administration.
Study NCT04818229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matched CBP-307
Description: Placebo-matched CBP-307 capsules oral administration.
Study NCT04818229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin (Avelox)
Description: Moxifloxacin tablets oral administration。
Study NCT04818229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matched Moxifloxacin
Description: Placebo-matched Moxifloxacin tablets oral administration.
Study NCT06641804 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pessary care, change of pessary
Description: Insertion of a new pessary by gynaecologist if not contraindicated, silicon or polyvinyl chloride pessary of same size, blinded to patient
Study NCT06641804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pessary care, change of pessary
Description: Insertion of a new pessary by gynaecologist if not contraindicated, silicon or polyvinyl chloride pessary of same size, blinded to patient
Study NCT06641375 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anti reflux endoscopic theraphy
Description: o the intervention arm, the area of cardia, along greater curvature will be cleaned first followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC using the H-APC catheter for marking and to prevent excess ablation . After this, the area of cardia, on either side will be injected in sequence using a combination of methylene blue and normal saline using the H-APC catheter jet system using between Effect 30 and Effect 70 on the ErbeJet 2 to raise the mucosa and create a submucosal cushion . Once adequate submucosal cushion is created, the mucosa starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W using the H-APC catheter till golden-brown discoloration of the ablated tissue20~The area of cardia below the Z-line will be treated in a 270-320-degree fashion. Once adequate ablation is achieved and no deeper tissue injury or bleeding is ensured, the procedure will be terminated.
Study NCT06641375 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopy
Description: Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.
Study NCT06094803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Zentangle Program
Description: Session 1 focuses on Self-awareness and Self-kindness through the Zentangle method. It covers the introduction, basic techniques, and eight steps of Zentangle. Participants practice mindfulness and learn grid and round patterns. Drawing mindfully and interactive sharing are encouraged for engagement and reflection.~Session 2 emphasizes Acceptance and Non-judgmental Attitude. It builds on the previous session, exploring advanced techniques in the Zentangle method. Participants practice mindfulness, learn organic and texturing patterns, create their own artwork, and engage in interactive sharing for reflection.
Study NCT04968834 — intervention group
Intervention type: GENETIC
Intervention: Genomic profiling
Description: Genomic profiling using CLIA assay
Study NCT06023264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: It is a minimally invasive treatment modality. Its effectiveness has been confirmed in numerous studies. It consists of applying an antiseptic in the puncture area and inserting the needle in the required aseptic conditions. During puncture, the patient's physical response is observed at all times, in order to control the local spasmodic responses in each muscle. After applying the technique, we assessed jaw pain, mouth opening, and the appearance of headaches. The adverse effects of the technique are the following: pain after puncture (1.7%), local bleeding at the puncture site (6.1%) and syncopal responses (0.7%).
Study NCT04938427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soticlestat placebo-matching mini-tablets or tablets.
Study NCT04938427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat mini-tablets or tablets.
Study NCT04625660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PQ Bypass System
Description: Intended use from CLN232 Rev A (CLN232 is the DETOUR2 Continued Access Protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis.
Study NCT05299424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336_group 1
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.04mg on C1D8, 0.04mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05603104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: See arm description
Study NCT05603104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second-line Antidepressants
Description: See arm description
Study NCT05603104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Second-line Antidepressants
Description: See arm description
Study NCT04678934 — intervention group
Intervention type: PROCEDURE
Intervention: TAVR
Description: Transcatheter aortic valve replacement
Study NCT05603104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Second-line Antipsychotics
Description: See arm description
Study NCT05603104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: See arm description
Study NCT05603104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine hydrochloride
Description: See arm description
Study NCT05414136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1006
Description: Intravenous fluids
Study NCT05553119 — intervention group
Intervention type: BEHAVIORAL
Intervention: Home Rehabilitation Monitoring System
Description: Established home-based pulmonary rehab system consists of three commercial devices (Garmin Vívofit™ activity monitor, Nonin 3150 WristOx2® Pulse Oximeter, Android tablet) and two software applications for telemonitored home pulmonary rehabilitation.
Study NCT05553119 — intervention group
Intervention type: BEHAVIORAL
Intervention: Health coaching calls
Description: Coaching calls based on motivational interviewing principles will occur weekly for twelve weeks following a standard protocol, lasting no more than 5-10 minutes.
Study NCT05038969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stomopral
Description: 1 capsule contains 40 mg Esomeprazole
Study NCT05038969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Description: 1 capsule contains 40 mg Esomeprazole
Study NCT05139732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: In order to investigate the metabolic profile, magnetic resonance spectroscopy (MRS) will be applied. Functional MRI (fMRI) allows to indirectly track cell activation measuring the blood-level dependent signal changes followed spontaneously (in resting state) or evoked by a task. Diffusion weighted imaging (DWI) is based on the differences in motion of the water molecules given by the underlying microarchitecture of the nervous tissue. Diffusion tensor imaging (DTI) allows visualisation of the nerve bundles and alterations thereof. Thus, microstructural alterations can be measured.
Study NCT05382286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously
Study NCT05382286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered intravenously
Study NCT05299424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336_group 2a
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05299424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336_group 2b
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 0.2mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05299424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336_group 3a
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 5.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05299424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336_group 3b
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05299424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336_group 4a
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 5.0mg on C1D8, 15.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05299424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336_group 4b
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 2.0mg on C1D8, 2.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05299424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336_group 5
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 8.0mg on C1D8, 24.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05299424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336_group 6a
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 10.0mg on C1D8, 40.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.